FDA Approves Groundbreaking SIMLANDI as First Interchangeable, High-Concentration Biosimilar to Humira

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimil...

February 26, 2024 | Monday | News
Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...

February 19, 2024 | Monday | News
dsm-firmenich Forges Exclusive Partnership with ZERION Pharma A/S to Pioneer Patient-Centric Cannabinoid Formulations

The partnership grants dsm-firmenich global access to ZERION A/S’s unique, cutting-edge Dispersome® technology, developed with the aim of signifi...

February 15, 2024 | Thursday | News
Corvus Pharmaceuticals Receives Orphan Drug Designation for Soquelitinib in T Cell Lymphoma, Advances Towards Phase 3 Clinical Trial

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a distinguished player in the clinical-stage biopharmaceutical arena, has achieved a significant milestone wit...

February 12, 2024 | Monday | News
Biocon Biologics and Sandoz Australia Forge Partnership for Biosimilars Trastuzumab and Bevacizumab

Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...

February 09, 2024 | Friday | News
Wegovy Producer Catalent Snapped Up in $16.5 Billion Deal by Novo Holdings

In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...

February 05, 2024 | Monday | News
Sandoz Introduces Tyruko® Biosimilar for MS, a Milestone in Germany

Tyruko® approved for all indications of reference medicine  Tyruko® biosimilar to treat adults with highly active relapsing remitting multi...

January 31, 2024 | Wednesday | News
Glenmark Secures License Agreement for Envafolimab in Key Global Territories

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East...

January 29, 2024 | Monday | News
InnoCare Initiates Clinical Trial for Zurletrectinib in China, Administering First Dose to Pediatric Patient

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...

January 24, 2024 | Wednesday | News
Bristol Myers Squibb Acquires Mirati Therapeutics, Bolstering Oncology Portfolio

“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...

January 23, 2024 | Tuesday | News
Vivtex Enters Research Collaboration with Astellas Pharma

Maureen Deehan, CEO of Vivtex, commented: “We are delighted to enter this new collaboration with Astellas Pharma. Over the past few years, Vivtex has...

January 23, 2024 | Tuesday | News
SGD Pharma Boosts Siliconized Glass Vial Capacity with New Line in France

Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, ...

January 22, 2024 | Monday | News
Simona Grandits Explores QIAGEN's Vision for Middle East Healthcare: Strategic Moves, Collaborations, and Technological Advancements

BioPharma BoardRoom sat down with Simona Grandits, Senior Director, Head of Sales and Marketing EEMEA at QIAGEN, to delve into the company's recent strateg...

January 18, 2024 | Thursday | Interview
Xeris Biopharma Secures Exclusive Global License for Xeriject® Formulation of Teprotumumab

“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneou...

January 11, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in